TEVA PHARMA IND. | Sales 2024 * | 15.86B 1,323B | Sales 2025 * | 16.35B 1,363B | Capitalization | 15.64B 1,304B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.54B 128B | Net income 2025 * | 1.44B 120B | EV / Sales 2024 * | 1.91 x |
| Net Debt 2024 * | 14.62B 1,219B | Net Debt 2025 * | 12.12B 1,010B | EV / Sales 2025 * | 1.7 x |
| P/E ratio 2024 * |
11.1
x | P/E ratio 2025 * |
10.3
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
More news
Teva Pharmaceutical Industries Limited is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
